丹麦制药巨头诺和诺德最近发布了2025上半年财报，“减肥神药”司美格鲁肽三款剂型实现1127.56亿丹麦克朗（约167亿美元）的销售额，合计贡献近73%的营收，这被视作司美格鲁肽正式接过K药全球“药王”权杖的关键一刻。

Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

在此前不久公布的财报中，诺和诺德披露2025年上半年司美格鲁肽的合计销售额约为166.32亿美元。目前司美格鲁肽一共被开发成了三款产品：即Ozempic（降糖注射剂）、Rybelsus（降糖口服剂）和Wegovy（减重注射剂），今年上半年，这三款产品 ...

If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 ...

On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...